


Supplementary file

J Diab Invest. Januszewski A.S. et al. **Haptoglobin Phenotype and Levels in Type 2 Diabetes and Effects of Fenofibrate.**

Figure 1

Flow chart of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study (left, reproduced from Cardiovasc Diabetol vol 3, issue 1, page 9 (2004).

<https://doi.org/10.1186/1475-2840-3-9>) and the timepoints for samples selection for these analyses (right).



Supplementary file

J Diab Invest. Januszewski A.S. et al. **Haptoglobin Phenotype and Levels in Type 2 Diabetes and Effects of Fenofibrate.**

Table 1

Comparison of clinical chemistry results at baseline and at the end of trial run-in (post 6 weeks of fenofibrate treatment).

	Baseline	End of 6-week fenofibrate 'run-in'	p*
HbA1c (%)**	6.8 ±1.3	7.2±1.4	0.0002
HbA1c (mmol/mol)**	50.4±14.5	54.9±15.6	0.0002
BMI (kg/m ²)	30.8±5.6	30.7±5.6	0.20
TC (mmol/L)	5.0±0.7	4.4±0.7	<0.0001
TG (mmol/L)	1.7 (1.3, 2.3)	1.2 (0.9, 1.6)	<0.0001
HDL-C (mmol/L)	1.1±0.3	1.2±0.3	<0.0001
LDL-C (mmol/L)	3.0±0.7	2.6±0.6	<0.0001
SBP (mmHg)	138±14	134±16	<0.0001
DBP (mmHg)	81±8	80±10	<0.0001
MAP (mmHg)	100±9	98±10	<0.0001
eGFR (CKD-EPI)	95 (83, 102)	85 (72, 96)	<0.0001

* – p-value: paired t-test or Wilcoxon test.

** – HbA1c: baseline and 2 years values (16 weeks results not available), n=100 (subject randomised to receive fenofibrate treatment).